



**HAL**  
open science

## MCR-1 and OXA-48 In Vivo Acquisition in KPC-Producing *Escherichia coli* after Colistin Treatment

Racha Beyrouthy, Frédéric Robin, Aude Lessene, Igor Lacombat, Laurent Dortet, Thierry Naas, Valérie Ponties, Richard Bonnet

► **To cite this version:**

Racha Beyrouthy, Frédéric Robin, Aude Lessene, Igor Lacombat, Laurent Dortet, et al.. MCR-1 and OXA-48 In Vivo Acquisition in KPC-Producing *Escherichia coli* after Colistin Treatment. *Antimicrobial Agents and Chemotherapy*, 2017, 61 (8), pp.e02540-16. 10.1128/AAC.02540-16 . hal-01639753

**HAL Id: hal-01639753**

**<https://uca.hal.science/hal-01639753v1>**

Submitted on 15 Nov 2018


**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Copyright



# MCR-1 and OXA-48 *In Vivo* Acquisition in KPC-Producing *Escherichia coli* after Colistin Treatment

Racha Beyrouthy,<sup>a,b,c</sup> Frederic Robin,<sup>a,b,c</sup> Aude Lessene,<sup>d</sup> Igor Lacomat,<sup>e</sup> Laurent Dortet,<sup>f,g,h</sup>  Thierry Naas,<sup>f,g,h</sup> Valérie Ponties,<sup>i</sup> Richard Bonnet<sup>a,b,c</sup>

CHU Clermont-Ferrand, Laboratoire de Bactériologie Clinique, Clermont-Ferrand, France<sup>a</sup>; Centre National de Référence de la Résistance aux Antibiotiques, laboratoire associé, Clermont-Ferrand, France<sup>b</sup>; Université Clermont Auvergne, UMR INSERM 1071, USC INRA2018, Clermont-Ferrand, France<sup>c</sup>; Laboratoire Jacques Cartier, Hôpital privé Jacques Cartier, Massy, France<sup>d</sup>; Service de Réanimation, Hôpital privé Jacques Cartier, Massy, France<sup>e</sup>; EA7361, Université Paris-Sud, Université Paris-Saclay, LabEx Lermite, Bacteriology-Hygiene Unit, APHP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France<sup>f</sup>; Associated French National Reference Center for Antibiotic Resistance: Carbapenemase-Producing Enterobacteriaceae, Le Kremlin-Bicêtre, France<sup>g</sup>; Evolution and Ecology of Resistance to Antibiotics Unit, Institut Pasteur-APHP-Université Paris Sud, Paris, France<sup>h</sup>; Santé Publique France, Saint-Maurice, France<sup>i</sup>

**ABSTRACT** The spread of *mcr-1*-encoding plasmids into carbapenem-resistant *Enterobacteriaceae* raises concerns about the emergence of untreatable bacteria. We report the acquisition of *mcr-1* in a carbapenem-resistant *Escherichia coli* strain after a 3-week course of colistin in a patient repatriated to France from Portugal. Whole-genome sequencing revealed that the *Klebsiella pneumoniae* carbapenemase-producing *E. coli* strain acquired two plasmids, an IncL OXA-48-encoding plasmid and an IncX4 *mcr-1*-encoding plasmid. This is the first report of *mcr-1* in carbapenemase-encoding bacteria in France.

**KEYWORDS** colistin, *Escherichia coli*, KPC-28, KPC-3, OXA-48, antibiotic resistance,  $\beta$ -lactamases, carbapenemase, *mcr-1*

Colistin is a last-resort antibiotic reserved for treating multidrug-resistant Gram-negative bacilli. However, the increased use of colistin in clinical treatment and agricultural and animal production has led to the emergence of bacterial resistance to the drug. In November 2015, the first transferable plasmid-mediated colistin resistance gene, *mcr-1*, was detected in China in retail meat and human samples (1). The gene was observed worldwide a few months later. The spread of *mcr-1*-encoding plasmids into carbapenem-resistant *Enterobacteriaceae* (2–5) is causing concern about the rise of untreatable bacteria (6).

In this work, we report an *in vivo* acquisition of *mcr-1* in carbapenemase-producing *Escherichia coli* after a 3-week course of colistin in a patient repatriated to France from Portugal in 2016. The 44-year-old man was hospitalized in Portugal for 2 months after a traffic accident. He had multiple traumas, including a thoracic injury associated with a respiratory *Enterobacter cloacae* infection that was treated with a combination of piperacillin and tazobactam. Carbapenemase-producing *Enterobacteriaceae* (CPE) belonging to the species *Klebsiella pneumoniae* and *E. coli* were isolated from a stool sample after treatment. A second episode of lower respiratory tract infection involving *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and the carbapenemase-producing *K. pneumoniae* was successfully treated by a 20-day course of colistin. The patient was then repatriated to an intensive care unit in France, where two *E. coli* isolates designated W11 and W12 were recovered from a feces CPE screening sample taken on the patient's admission with CarbaSmart medium (bioMérieux, La Balme, France).

The *E. coli* W11 and W12 isolates were resistant to penicillins, oxy-imino-

Received 29 November 2016 Returned for modification 29 November 2016 Accepted 13 April 2017

Accepted manuscript posted online 15 May 2017

**Citation** Beyrouthy R, Robin F, Lessene A, Lacomat I, Dortet L, Naas T, Ponties V, Bonnet R. 2017. MCR-1 and OXA-48 *in vivo* acquisition in KPC-producing *Escherichia coli* after colistin treatment. Antimicrob Agents Chemother 61:e02540-16. <https://doi.org/10.1128/AAC.02540-16>.

**Copyright** © 2017 American Society for Microbiology. All Rights Reserved.

Address correspondence to Richard Bonnet, rbonnet@chu-clermontferrand.fr.

**TABLE 1** Susceptibilities of the studied strains to  $\beta$ -lactams, by microdilution method

Strain	Carbapenemase-encoding genes	MIC ( $\mu\text{g/ml}$ ) of <sup>a</sup> :							
		AMX	FOX	CAZ	CTX	FEP	IPM	ETP	MEM
WI1	<i>bla</i> <sub>KPC-3</sub>	>256	16	>256	>32	12	4	6	2
WI2	<i>bla</i> <sub>KPC-28r</sub> , <i>bla</i> <sub>OXA-48</sub>	>256	8	>256	8	6	1	3	0.38
<i>E. coli</i> DH5 $\alpha$ -KPC-3	<i>bla</i> <sub>KPC-3</sub>	>256	8	4	1	1	1	0.125	0.25
<i>E. coli</i> DH5 $\alpha$ KPC-28	<i>bla</i> <sub>KPC-28</sub>	64	8	64	0.5	1	0.125	0.032	0.032
<i>E. coli</i> DH5 $\alpha$		1	4	0.06	0.06	0.032	0.05	0.006	0.006

<sup>a</sup>AMX, amoxicillin; FOX, ceftaxime; CAZ, ceftazidime; CTX, cefotaxime; FEP, cefepime; IPM, imipenem; ETP, ertapenem; MEM, meropenem.

cephalosporins, and carbapenems. The colistin MIC (broth microdilution method) was in the sensitive range (0.25  $\mu\text{g/ml}$ ) for the WI1 isolate. In contrast, the MIC was in the resistance range for the *E. coli* WI2 isolate, with a value of 4  $\mu\text{g/ml}$ , as usually observed for *mcr-1*-harboring *E. coli*. The whole-genome sequence (WGS) of strain WI2 was determined by hybrid *de novo* assembly of 2 $\times$  150-bp paired-end reads generated with Illumina sequencing technology (San Diego, CA, USA) and long reads generated with Pacific Biosciences RS II SMRT technology (Menlo Park, CA, USA). WGS of strain WI1 was determined by *de novo* assembly of 2 $\times$  150-bp paired-end reads (Illumina) and mapping to the genome of strain WI2. *De novo* assemblies were performed with SPAdes (7), the mappings with Burrows-Wheeler aligner (8), and the final polishing of the assembly with Pilon (9). The average depth sequencing (ADS) was 125 $\times$  and 145 $\times$  for WI1 and WI2 chromosomes (4.8 Mb), respectively. Three plasmids were detected in strain WI1 (ADS, 282 $\times$  to 320 $\times$ ; sizes, 54,502 to 83,831 bp) and five in strain WI2 (ADS, 81 $\times$  to 213 $\times$ ; sizes, 33,304 to 83,832 bp). The plasmid content of the strains and the size of the plasmids were confirmed with plasmid DNA extracted by alkaline lysis, as previously described (10).

The antibiotic resistance genes were detected with the Comprehensive Antibiotic Resistance Database (CARD) (11). *E. coli* WI1 did not harbor *mcr-1* but did harbor the carbapenemase-encoding gene *bla*<sub>KPC-3</sub>. In contrast, *E. coli* WI2 harbored the *mcr-1* gene and two carbapenemase-encoding genes, *bla*<sub>OXA-48</sub> and a *bla*<sub>KPC-3</sub> variant gene designated *bla*<sub>KPC-28</sub> (accession number KY282958). The sequence of *bla*<sub>KPC-28</sub> was confirmed by PCR and Sanger sequencing. The deduced amino acid sequence of KPC-28 was derived from KPC-3 by two amino acid deletions in the catalytic pocket at positions 241 and 242. The KPC-28- and KPC-3-encoding open reading frames were cloned in *E. coli* DH5 $\alpha$  with pBK-CMV vector (Stratagene, San Diego, CA, USA). MIC values suggested that the deletions at positions 241 and 242 decrease the activity against amoxicillin and carbapenems but improve the activity against ceftazidime (Table 1). Isolates WI1 and WI2 shared the other antimicrobial resistance gene contents (*strA*, *strB*, *folP*, and *tetBDR*), and no mutation was detected in chromosomal genes involved in quinolone (*gyrA*, *gyrB*, *parC*, and *parE*) and colistin (*mgrB*, *pmrAB*, and *phoPQ*) resistance.

The isolates were typed from WGSs by assigning sequence types according to the MLST Warwick University website. WI1 and WI2 belonged to sequence type ST1288 and *E. coli* phylogroup C (12). Single nucleotide polymorphism calling was performed from alignments generated by parsnip in deeply sequenced regions (>60 $\times$ ) (13), which were filtered for repeat elements, phages, and putative recombination events. Among 4,219,421 bp, WI1 and WI2 diverged by only four single nucleotide variants (SNVs) and were therefore determined to be two isolates of the same strain.

The assembled genomes were analyzed by PlasmidFinder (<http://www.genomicepidemiology.org/>) using the *Enterobacteriaceae* database with the detection thresholds set at 95% sequence identity. Three replicons (IncN, IncFII, and IncI1) were shared by both isolates. However, WI2 contained two additional replicons (IncX4 and IncL). The 33,304-bp-long IncX4 plasmid, designated pWI2-mcr, harbored *mcr-1* and encoded no other antimicrobial resistance gene. The most closely related plasmid is the unpublished *mcr-1*-harboring plasmid pICBEC72Hmcr characterized in Brazil

(CP015977). The pWI2-mcr sequence covered 99.98% of the pICBEC72Hmcr plasmid sequence and differed from the latter by only four SNVs.

A 62,645-bp-long IncI plasmid, designated pWI2-OXA48, carried *bla*<sub>OXA-48</sub>. pWI2-OXA48 differed from the pOXA-48a reference plasmid by a 2,762-bp deletion (14). The deletion occurred within *orf25* at base 22,738, leading to the suppression of *ccgA1* and *orf26* genes. The deleted region was replaced by insertion sequence *IS1R*, which is probably involved in this novel arrangement within the backbone of a pOXA-48-like plasmid (15).

In the WI1 and WI2 isolates, *bla*<sub>KPC-3</sub> and *bla*<sub>KPC-28</sub> were carried by ST15-IncN 54,518-bp and 54,533-bp plasmids, designated pWI1-KPC3 and pWI2-KPC28, respectively. The plasmid pWI2-KPC28 differed from pWI1-KPC3 by the deletion of 6 bp, which generated the new *bla*<sub>KPC</sub> variant. A 21-bp deletion occurred within hypothetical protein (49,871 to 50,728 bp) in pWI1-KPC3. No additional resistant gene was detected in these plasmids. The two strains also contained two identical plasmids devoid of antibiotic resistance genes and belonging to incompatibility groups IncI1 (83,831 bp) and IncFII (60,622 bp).

In conclusion, our data support the *in vivo* acquisition of *mcr-1*- and *bla*<sub>OXA-48</sub>-bearing plasmids by a KPC-producing *E. coli* probably following treatment with colistin. The emergence of multidrug-resistant isolates, such as *E. coli* WI2, that need to be carefully monitored is becoming a major burden on health care systems worldwide.

**Accession number(s).** The complete genome sequences of WI1 and WI2 strains were deposited in EMBL/GenBank under assembly accession numbers [LT838196](#), [LT838197](#), [LT838198](#), and [LT838199](#) (WI1) and [LT838200](#), [LT838201](#), [LT838202](#), [LT838203](#), and [LT838204](#) (WI2).

## ACKNOWLEDGMENTS

We are grateful to Henrik Hasman and Frank Hansen for kindly providing the *mcr-1* *E. coli* ESB20150072. We thank Alexis Pontvianne and Laurent Guillouard for technical assistance.

This work was supported by the National Institute for Agronomic Research (INRA, USC-2018), the Centre Hospitalier Universitaire de Clermont-Ferrand, and Santé Publique France.

## REFERENCES

- Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, Yu LF, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu JH, Shen J. 2016. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. *Lancet Infect Dis* 16:161–168. [https://doi.org/10.1016/S1473-3099\(15\)00424-7](https://doi.org/10.1016/S1473-3099(15)00424-7).
- Yu H, Qu F, Shan B, Huang B, Jia W, Chen C, Li A, Miao M, Zhang X, Bao C, Xu Y, Chavda KD, Tang YW, Kreiswirth BN, Du H, Chen L. 2016. Detection of the *mcr-1* colistin resistance gene in carbapenem-resistant *Enterobacteriaceae* from different hospitals in China. *Antimicrob Agents Chemother* 60:5033–5035. <https://doi.org/10.1128/AAC.00440-16>.
- Falgenhauer L, Waezsada SE, Yao Y, Imirzalioglu C, Käsbohrer A, Roesler U, Michael GB, Schwarz S, Werner G, Kreienbrock L, Chakraborty T. 2016. Colistin resistance gene *mcr-1* in extended-spectrum  $\beta$ -lactamase-producing and carbapenemase-producing Gram-negative bacteria in Germany. *Lancet Infect Dis* 16:282–283. [https://doi.org/10.1016/S1473-3099\(16\)00009-8](https://doi.org/10.1016/S1473-3099(16)00009-8).
- Poirel L, Kieffer N, Liassine N, Thanh D, Nordmann P. 2016. Plasmid-mediated carbapenem and colistin resistance in a clinical isolate of *Escherichia coli*. *Lancet Infect Dis* 16:281. [https://doi.org/10.1016/S1473-3099\(16\)00006-2](https://doi.org/10.1016/S1473-3099(16)00006-2).
- Zhi C, Lv L, Yu LF, Doi Y, Liu JH. 2016. Dissemination of the *mcr-1* colistin resistance gene. *Lancet Infect Dis* 16:292–293. [https://doi.org/10.1016/S1473-3099\(16\)00063-3](https://doi.org/10.1016/S1473-3099(16)00063-3).
- Hasman H, Hammerum AM, Hansen F, Hendriksen RS, Olesen B, Agersø Y, Zankari E, Leekitcharoenphon P, Stegger M, Kaas RS, Cavaco LM, Hansen DS, Aarestrup FM, Skov RL. 2015. Detection of *mcr-1* encoding plasmid-mediated colistin-resistant *Escherichia coli* isolates from human bloodstream infection and imported chicken meat, Denmark 2015. *Euro Surveill* 20. <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=21331>.
- Nurk S, Bankevich A, Antipov D, Gurevich AA, Korobeynikov A, Lapidus A, Prjibelski AD, Pyshkin A, Sirotkin A, Sirotkin Y, Stepanauskas R, Clin-genpeel SR, Woyke T, McLean JS, Lasken R, Tesler G, Alekseyev MA, Pevzner PA. 2013. Assembling single-cell genomes and mini-metagenomes from chimeric MDA products. *J Comput Biol* 20:714–737. <https://doi.org/10.1089/cmb.2013.0084>.
- Li H, Durbin R. 2009. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 25:1754–1760. <https://doi.org/10.1093/bioinformatics/btp324>.
- Walker BJ, Abeel T, Shea T, Priest M, Abouelliel A, Sakthikumar S, Cuomo CA, Zeng Q, Wortman J, Young SK, Earl AM. 2014. Pilon: an integrated tool for comprehensive microbial variant detection and genome assembly improvement. *PLoS One* 9:e112963. <https://doi.org/10.1371/journal.pone.0112963>.
- Beyrouthy R, Robin F, Hamze M, Bonnet R. 2017. IncFIIk plasmid harbouring an amplification of 16S rRNA methyltransferase-encoding gene *rmtH* associated with mobile element ISCR2. *J Antimicrob Chemother* 72:402–406. <https://doi.org/10.1093/jac/dkw435>.
- Jia B, Raphenya AR, Alcock B, Wagglechner N, Guo P, Tsang KK, Lago BA, Dave BM, Pereira S, Sharma AN, Doshi S, Courtot M, Lo R, Williams LE, Frye JG, Elsayegh T, Sardar D, Westman EL, Pawlowski AC, Johnson TA, Brinkman FSL, Wright GD, McArthur AG. 2017. CARD 2017: expansion and model-centric curation of the comprehensive antibiotic resistance database. *Nucleic Acids Res* 45:D566–D573. <https://doi.org/10.1093/nar/gkw1004>.

12. Clermont O, Christenson JK, Denamur E, Gordon DM. 2013. The Clermont *Escherichia coli* phylo-typing method revisited: improvement of specificity and detection of new phylo-groups. *Environ Microbiol Rep* 5:58–65. <https://doi.org/10.1111/1758-2229.12019>.
13. Treangen TJ, Ondov BD, Koren S, Phillippy AM. 2014. The Harvest suite for rapid core-genome alignment and visualization of thousands of intraspecific microbial genomes 1–15. *Genome Biol* 15:524. <https://doi.org/10.1186/s13059-014-0524-x>.
14. Poirel L, Bonnin RA, Nordmann P. 2012. Genetic features of the widespread plasmid coding for the carbapenemase OXA-48. *Antimicrob Agents Chemother* 56:559–562. <https://doi.org/10.1128/AAC.05289-11>.
15. Beyrouthy R, Robin F, Delmas J, Gibold L, Dalmasso G, Dabboussi F, Hamzé M, Bonnet R. 2014. IS1R-mediated plasticity of IncL/M plasmids leads to the insertion of *bla*<sub>OXA-48</sub> into the *Escherichia coli* chromosome. *Antimicrob Agents Chemother* 58:3785–3790. <https://doi.org/10.1128/AAC.02669-14>.